Key Dates

Related Announcements

RFA-CA-22-045 - NCI Outstanding Investigator Award (R35 Clinical Trial Optional)

Issued by

National Cancer Institute (NCI)

Purpose

The purpose of this Notice is to inform the applicant community about resubmissions to RFA-CA-22-045, NCI Outstanding Investigator Award (R35 Clinical Trial Optional).

Applicants are reminded that NIH policy (NOT-OD-18-197) requires that if an application was submitted to a PAR, the subsequent submission to an RFA must be formatted as a New (Type 1 A0) application. Such applications may not be formatted as resubmission (Type 1 A1) or renewal resubmission (Type 2 A1). New applications may not refer to a prior funding period or review. Applicants are referred to NOT-OD-18-197 Addendum A. Compliance with Requirements for New Applications for more information.

Once an application has been reviewed under the RFA it will be eligible to submit as a resubmission.

Inquiries

Please direct all inquiries to:

Christine Siemon
National Cancer Institute (NCI)
Telephone: 240-276-6266
Email: [email protected]